<?xml version='1.0' encoding='utf-8'?>
<document id="24399452"><sentence text="Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir."><entity charOffset="37-45" id="DDI-PubMed.24399452.s1.e0" text="afatinib" /><entity charOffset="51-61" id="DDI-PubMed.24399452.s1.e1" text="rifampicin" /><entity charOffset="66-75" id="DDI-PubMed.24399452.s1.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.24399452.s1.e0" e2="DDI-PubMed.24399452.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s1.e0" e2="DDI-PubMed.24399452.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s1.e0" e2="DDI-PubMed.24399452.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s1.e1" e2="DDI-PubMed.24399452.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s1.e1" e2="DDI-PubMed.24399452.s1.e2" /></sentence><sentence text="Afatinib is a potent, irreversible, ErbB family blocker in clinical development for the treatment of advanced non-small cell lung cancer, metastatic head and neck cancer, and other solid tumours"><entity charOffset="0-8" id="DDI-PubMed.24399452.s2.e0" text="Afatinib" /></sentence><sentence text=" As afatinib is a substrate for the P-glycoprotein (P-gp) pump transporter the three studies presented here investigated the pharmacokinetics of afatinib in the presence of a potent inhibitor (ritonavir) or inducer [rifampicin (rifampin)] of P-gp"><entity charOffset="4-12" id="DDI-PubMed.24399452.s3.e0" text="afatinib" /><entity charOffset="145-153" id="DDI-PubMed.24399452.s3.e1" text="afatinib" /><entity charOffset="193-202" id="DDI-PubMed.24399452.s3.e2" text="ritonavir" /><entity charOffset="215-226" id="DDI-PubMed.24399452.s3.e3" text="[rifampicin" /><entity charOffset="228-236" id="DDI-PubMed.24399452.s3.e4" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e0" e2="DDI-PubMed.24399452.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e0" e2="DDI-PubMed.24399452.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e0" e2="DDI-PubMed.24399452.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e0" e2="DDI-PubMed.24399452.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e0" e2="DDI-PubMed.24399452.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e1" e2="DDI-PubMed.24399452.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e1" e2="DDI-PubMed.24399452.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e1" e2="DDI-PubMed.24399452.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e1" e2="DDI-PubMed.24399452.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e2" e2="DDI-PubMed.24399452.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e2" e2="DDI-PubMed.24399452.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e2" e2="DDI-PubMed.24399452.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e3" e2="DDI-PubMed.24399452.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24399452.s3.e3" e2="DDI-PubMed.24399452.s3.e4" /></sentence><sentence text="" /><sentence text="We conducted phase I, open-label, single-centre studies in healthy male volunteers who received a single once-daily oral dose of afatinib (20 or 40 mg) together with either ritonavir or rifampicin; two studies had a randomised, two- and three-way crossover design and the third was a non-randomised, two-period sequential study"><entity charOffset="129-137" id="DDI-PubMed.24399452.s5.e0" text="afatinib" /><entity charOffset="173-182" id="DDI-PubMed.24399452.s5.e1" text="ritonavir" /><entity charOffset="186-196" id="DDI-PubMed.24399452.s5.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24399452.s5.e0" e2="DDI-PubMed.24399452.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s5.e0" e2="DDI-PubMed.24399452.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s5.e0" e2="DDI-PubMed.24399452.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s5.e1" e2="DDI-PubMed.24399452.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s5.e1" e2="DDI-PubMed.24399452.s5.e2" /></sentence><sentence text="" /><sentence text="When afatinib 20 mg was administered 1 h after ritonavir, afatinib geometric mean (gMean) maximum plasma concentration (C max) and area under the plasma concentration-time curve from time zero to infinity (AUC∞) increased by 38"><entity charOffset="5-13" id="DDI-PubMed.24399452.s7.e0" text="afatinib" /><entity charOffset="47-56" id="DDI-PubMed.24399452.s7.e1" text="ritonavir" /><entity charOffset="58-66" id="DDI-PubMed.24399452.s7.e2" text="afatinib" /><pair ddi="false" e1="DDI-PubMed.24399452.s7.e0" e2="DDI-PubMed.24399452.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s7.e0" e2="DDI-PubMed.24399452.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s7.e0" e2="DDI-PubMed.24399452.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24399452.s7.e1" e2="DDI-PubMed.24399452.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24399452.s7.e1" e2="DDI-PubMed.24399452.s7.e2" /></sentence><sentence text="5 and 47" /><sentence text="6 %, respectively" /><sentence text=" Coadministration of ritonavir either simultaneously or 6 h later than afatinib 40 mg resulted in minimal increase in the afatinib gMean C max and AUC∞ (4"><entity charOffset="21-30" id="DDI-PubMed.24399452.s10.e0" text="ritonavir" /><entity charOffset="71-79" id="DDI-PubMed.24399452.s10.e1" text="afatinib" /><pair ddi="false" e1="DDI-PubMed.24399452.s10.e0" e2="DDI-PubMed.24399452.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s10.e0" e2="DDI-PubMed.24399452.s10.e1" /></sentence><sentence text="1 and 18" /><sentence text="6 % for simultaneous administration with AUC∞ not completely within the bioequivalence limits; 5" /><sentence text="1 and 10" /><sentence text="8 % for timed administration within the bioequivalence limits)" /><sentence text=" Administration of afatinib 40 mg in the presence of rifampicin led to reduction in C max and AUC∞ by 21"><entity charOffset="19-27" id="DDI-PubMed.24399452.s15.e0" text="afatinib" /><entity charOffset="53-63" id="DDI-PubMed.24399452.s15.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24399452.s15.e0" e2="DDI-PubMed.24399452.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24399452.s15.e0" e2="DDI-PubMed.24399452.s15.e1" /></sentence><sentence text="6 and 33" /><sentence text="8 %, respectively" /><sentence text=" In all studies, P-gp modulation mainly affected the extent of absorption of afatinib; there was no change in the terminal elimination half-life"><entity charOffset="77-85" id="DDI-PubMed.24399452.s18.e0" text="afatinib" /></sentence><sentence text=" The overall safety profile of afatinib was acceptable"><entity charOffset="31-39" id="DDI-PubMed.24399452.s19.e0" text="afatinib" /></sentence><sentence text="" /><sentence text="Coadministration of potent P-gp modulators had no clinically relevant effect on afatinib exposure"><entity charOffset="80-88" id="DDI-PubMed.24399452.s21.e0" text="afatinib" /></sentence><sentence text=" Effects of potent P-gp inhibitors were minimal at higher afatinib doses and can be readily managed by the timing of concomitant therapy"><entity charOffset="58-66" id="DDI-PubMed.24399452.s22.e0" text="afatinib" /></sentence><sentence text=" As afatinib is not a relevant modulator or substrate of cytochrome P450 enzymes, the drug-drug interaction potential is considered to be low"><entity charOffset="4-12" id="DDI-PubMed.24399452.s23.e0" text="afatinib" /></sentence><sentence text="" /></document>